NEW YORK - HOOKIPA Pharma Inc., a biotechnology company focused on developing immunotherapies, has made a public opening position disclosure in accordance with the Takeover Code, according to a statement released on January 8, 2025. The disclosure is related to HOOKIPA Pharma Inc. itself, with the company being both the discloser and the offeror.
As of January 7, 2025, HOOKIPA Pharma reported no interests or short positions in its common stock with a par value of $0.0001 per share. Furthermore, the company confirmed that no cash-settled or stock-settled derivatives positions were held, including any options or agreements to purchase or sell relevant securities.
The disclosure also detailed the interests held by the directors of HOOKIPA Pharma Inc., their close relatives, and related trusts. Notably, the directors hold various stock options under the company's 2019 Stock Option and Incentive Plan, with different vesting dates and exercise prices. The largest number of shares under option for a single plan is 108,695, granted to Malte Peters with vesting dates yet to be announced.
The filing clarified that there are no indemnity or option arrangements, or any agreements or understandings, formal or informal, that may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it. Additionally, there are no agreements, arrangements, or understandings relating to the voting rights of any relevant securities under any option, or the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced.
This disclosure, mandated by the Takeover Code, is part of the regulatory process in mergers and acquisitions, ensuring transparency for shareholders and the market. It is important for investors to note that this information is based on a press release statement from HOOKIPA Pharma Inc. and does not imply any further actions or outcomes related to the takeover process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.